Skip to main content

Day: January 15, 2024

Healthcare Electronic Data Interchange Market Size Worth USD 11.41 Billion in 2032 | Emergen Research

Rising adoption of EDI, and rapid technological advancements in Healthcare EDI are key factors driving healthcare Electronic Data Interchange (EDI) market revenue growth. Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) — The global healthcare Electronic Data Interchange (EDI) market size was USD 4.56 Billion in 2022 and is expected to register a rapid revenue CAGR of 9.8% during the forecast period. Rising adoption of EDI, and rapid technological advancements in Healthcare EDI are key factors driving market revenue growth. A key trend in the market is rapid technological advancements in the healthcare EDI. Among the most significant advancements in healthcare EDI market over the past year is the development of bio-Cloud based EDI solution. This is a significant development because it helps to improve the efficiency and interoperability...

Continue reading

Correction: Hermès International: Shares and voting rights as of 31st December 2023

RELEASE Paris, January 15, 2024 INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES COMPRISING THE SHARE CAPITALIn accordance with the provisions of Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF), Hermès international publishes each month, before the 15th day of the following month, the total number of voting rights and the number of shares comprising the share capital if they have varied from those previously published.Date Total number of shares Total number of theoretical voting rights (including treasury stock) Total number of effective voting rights (exercisable at shareholders’ meetings) Publications31 December 2023 105 569 412 179 317 667 1 178 478 552 1 15 January 2024...

Continue reading

Ipsos acquires Jarmany, a company specialising in data management and analytics in the UK

Ipsos acquires Jarmany, a company specialising in data management and analytics in the UK Paris, January 15th, 2024 – Ipsos, one of the world’s leading market research companies, announces the acquisition of Jarmany, a company renowned for its expertise in data analytics and strategy in the UK. Founded in 2008, Jarmany supports a range of international companies in their operational, financial and strategic decision-making. Its expertise is grounded in the aggregation, analysis and visualisation of data, in particular through the use of artificial intelligence. The company will continue to be led by its co-founders, Matthew Rhodes and Tom Hunt. The Jarmany team joins the Ipsos business in the UK, with whom they will work closely to develop their capabilities in integrating diverse and complex datasets. Ben Page, Chief Executive...

Continue reading

Boussard & Gavaudan Holding Ltd (EUR): Newsletter December 2023

Good evening, Please find enclosed BGHL December 2023 Newsletter. Best regards, Enquiries: Boussard & Gavaudan Investment Management, LLP Email: info@bgam-uk.com This document is issued by Boussard & Gavaudan Investment Management, LLP. which is authorised and regulated in the conduct of investment business by the Financial Conduct Authority in the United Kingdom. This document is for information purposes only and is not an offer to invest. Boussard & Gavaudan Holding Limited is a closed-ended investment company incorporated under the laws of Guernsey. Boussard & Gavaudan Holding Limited is registered with the Dutch Authority for Financial Markets as a collective investment scheme under article 1.107 of the Dutch Financial Markets Supervision Act. All investment is subject to risk. Past performance is no guarantee...

Continue reading

Voltalia SA:Total number of shares and voting rights in the share capital as of December 31, 2023 

Total number of shares and voting rights in the share capital as of December 31, 2023 (Articles L. 233-8 (II) of the French Commercial Code and 223-16 of the General Regulations of the French Financial Markets Authority) Date  Total number of shares in the capital   Number of theoretical voting rights  Number of exercisable voting rights 12/31/2023  131 318 716 197 646 226 197 278 926Next on the agenda: Q4 2023 Turnover, on January 31, 2024 (after market close)About Voltalia (www.voltalia.com)Voltalia is an international player in the renewable energy sector. The Group produces and sells electricity generated from wind, solar, hydraulic, biomass and storage facilities that it owns and operates. Voltalia has generating capacity in operation and under construction of more than 2.8 GW and a portfolio of projects...

Continue reading

Boussard & Gavaudan Holding Ltd (GBP): Newsletter December 2023

Good evening, Please find enclosed BGHL December 2023 Newsletter. Best regards, Enquiries: Boussard & Gavaudan Investment Management, LLP Email: info@bgam-uk.com This document is issued by Boussard & Gavaudan Investment Management, LLP. which is authorised and regulated in the conduct of investment business by the Financial Conduct Authority in the United Kingdom. This document is for information purposes only and is not an offer to invest. Boussard & Gavaudan Holding Limited is a closed-ended investment company incorporated under the laws of Guernsey. Boussard & Gavaudan Holding Limited is registered with the Dutch Authority for Financial Markets as a collective investment scheme under article 1.107 of the Dutch Financial Markets Supervision Act. All investment is subject to risk. Past performance is no guarantee...

Continue reading

Guerbet: Financial agenda for 2024

Financial agenda for 2024 Villepinte, 15 January 2024: Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024.Publications calendar2023 ANNUAL REVENUEFebruary 08, 2024, after trading2023 ANNUAL RESULTSMarch 20, 2024, after trading2024 1ST QUARTER REVENUEApril 25, 2024, after tradingANNUAL SHAREHOLDERS’ MEETINGMay 24, 20242024 2ND QUARTER REVENUEJuly 25, 2024, after trading2024 FIRST HALF RESULTSSeptember 25, 2024, after trading2024 3RD QUARTER REVENUEOctober 24, 2024, after trading    About Guerbet At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical...

Continue reading

Urinary Drainage Bags Market Size Worth USD 2.84 Billion in 2032 | Emergen Research

Rising elderly population, and increase in gynaecological and urological operations are some of the key factors driving Urinary Drainage Bags market revenue growth. Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) —  The global urinary drainage bags market size was USD 1.99 Billion in 2022 and is expected to register a revenue CAGR of 3.7% during the forecast period. Increasing prevalence of urological disorders, rising elderly population, and increase in gynaecological and urological operations are some of the key factors driving market revenue growth. Moreover, rising number of urinary infections is one the key factors driving revenue growth of the market. Urinary Tract Infections (UTIs) stand as one of the prevalent bacterial infections encountered in clinical settings. Their primary impact lies within the lower urinary tract, specifically...

Continue reading

Kojamo Plc: Kojamo increases bond maturing in 2029 by EUR 200 million as a private placement

Kojamo plc Stock Exchange Release, 15 January 2024 at 7:15 p.m EET Kojamo increases bond maturing in 2029 by EUR 200 million as a private placement On 22 January 2024, Kojamo plc will issue EUR 200 million unsecured green notes as a private placement. The new notes are issued under the company’s EMTN programme as an increase to the company’s notes maturing on 28 May 2029 (ISIN XS2345877497). The issue price of the new notes is 77.848%. The proceeds of the issue will be used for the refinancing of projects in accordance with the company’s Green Finance Framework.  “This is the first sizable euro-denominated bond issuance by a residential real estate company since 2022. We are very pleased to see the investors’ strong interest in the company, and this shows our access to diverse sources of funding,” says CFO Erik Hjelt. OP Corporate Bank...

Continue reading

AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2036 IN THE TREATMENT OF MASTOCYTOSIS THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY PROTECTION STRATEGY BASED ON MEDICAL USE PATENTS Paris, January 15, 2024, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis (i.e. a medical use patent) with its lead compound masitinib, based on findings from study AB06006 [1]. This new European patent provides intellectual property protection for masitinib in this indication until October 2036. The same medical use patent strategy had been successfully pursued in amyotrophic lateral sclerosis, with patent granted worldwide...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.